Assessing frequency and clinical outcomes of BRCA mutated ovarian cancer in Saudi women
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Assessing frequency and clinical outcomes of BRCA mutated ovarian cancer in Saudi women ; volume:22 ; number:1 ; day:3 ; month:1 ; year:2022 ; pages:1-9 ; date:12.2022
BMC cancer ; 22, Heft 1 (3.1.2022), 1-9, 12.2022
- Creator
-
Agha, Naela
Alshamsan, Bader
Al-Farsi, Sharifa
Ateya, Heba Aly
Almugbel, Fahad A.
Alotaibi, Hazem Abdullah
Omar, Ayman
Mohamed, Amgad Shahin
Alharthy, Hanan
Elhassan, Tusneem
Salem, Hany
Alhusaini, Hamed
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-021-09123-6
- URN
-
urn:nbn:de:101:1-2022042120075213272752
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Agha, Naela
- Alshamsan, Bader
- Al-Farsi, Sharifa
- Ateya, Heba Aly
- Almugbel, Fahad A.
- Alotaibi, Hazem Abdullah
- Omar, Ayman
- Mohamed, Amgad Shahin
- Alharthy, Hanan
- Elhassan, Tusneem
- Salem, Hany
- Alhusaini, Hamed
- SpringerLink (Online service)
Other Objects (12)
MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
BRCA germline mutation test for all woman with ovarian cancer?
Promoter hypomethylation, especially around the E26 transformation-specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer
Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
Hereditary Breast and Ovarian Cancer Syndrome (BRCA) Gene: Concept, Pathways, Therapeutics, and Future
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors
Variation of mutant allele frequency in NRAS Q61 mutated melanomas
Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
BRCA germline mutation test for all woman with ovarian cancer?
Promoter hypomethylation, especially around the E26 transformation-specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer
Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
Hereditary Breast and Ovarian Cancer Syndrome (BRCA) Gene: Concept, Pathways, Therapeutics, and Future
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors
Variation of mutant allele frequency in NRAS Q61 mutated melanomas
Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
BRCA germline mutation test for all woman with ovarian cancer?
Promoter hypomethylation, especially around the E26 transformation-specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer
Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
Hereditary Breast and Ovarian Cancer Syndrome (BRCA) Gene: Concept, Pathways, Therapeutics, and Future
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors
Variation of mutant allele frequency in NRAS Q61 mutated melanomas